Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) CFO Sells $1,050,000.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) CFO Michael Landsittel sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the transaction, the chief financial officer now owns 47,286 shares in the company, valued at approximately $4,965,030. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Landsittel also recently made the following trade(s):

• On Thursday, March 28th, Michael Landsittel sold 5,000 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.00, for a total transaction of $475,000.00.
• On Friday, March 15th, Michael Landsittel sold 13,734 shares of Blueprint Medicines stock. The stock was sold at an average price of $87.78, for a total transaction of $1,205,570.52.
• On Thursday, March 7th, Michael Landsittel sold 5,003 shares of Blueprint Medicines stock. The shares were sold at an average price of $90.69, for a total transaction of $453,722.07.

Blueprint Medicines Price Performance

NASDAQ:BPMC opened at $108.78 on Thursday. The company has a quick ratio of 3.61, a current ratio of 3.76 and a debt-to-equity ratio of 0.67. Blueprint Medicines Co. has a 52 week low of $43.89 and a 52 week high of $110.93. The stock’s 50-day moving average price is $92.44 and its 200-day moving average price is $82.00. The stock has a market capitalization of $6.66 billion, a PE ratio of -22.62 and a beta of 0.65.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million for the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. Blueprint Medicines’s quarterly revenue was up 85.5% compared to the same quarter last year. During the same period last year, the company earned ($2.65) earnings per share. As a group, equities analysts expect that Blueprint Medicines Co. will post -5.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BPMC has been the subject of a number of research reports. Piper Sandler lifted their price target on Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Barclays lifted their target price on Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, May 3rd. The Goldman Sachs Group increased their price target on shares of Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a report on Monday. Wedbush restated an “outperform” rating and set a $110.00 price objective on shares of Blueprint Medicines in a research note on Friday, April 26th. Finally, StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $100.31.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. grew its position in shares of Blueprint Medicines by 63.4% in the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 329 shares during the period. Cutler Group LLC CA increased its stake in Blueprint Medicines by 1,685.7% during the 3rd quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after buying an additional 944 shares in the last quarter. Headlands Technologies LLC increased its stake in Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after buying an additional 342 shares in the last quarter. Compass Wealth Management LLC acquired a new position in shares of Blueprint Medicines during the fourth quarter valued at approximately $69,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Blueprint Medicines by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 757 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.